Gilead Acquires Tubulis for $3.15B Upfront to Strengthen Oncology ADC Pipeline on April 07, 2026 acquisition ADC Gilead Neoplasms therapeutic autologous dendritic cells TUB-040 Tubulis +
Genmab Abandons ADC Asset Acquired in $1.8B ProfoundBio Deal on September 17, 2025 Acquisition ADC Antibody-Drug Conjugates Genmab Neoplasms ProfoundBio therapeutic autologous dendritic cells +
CytomX Continues Phase I ADC Study After Patient Death on August 14, 2025 ADC Clinical Trials Colorectal Carcinoma CX-2051 CytomX Kidney Failure, Acute Patient Death Phase I Safety therapeutic autologous dendritic cells United States Food and Drug Administration +
NextCure Partners with Simcere for Novel ADC in $745M Deal on June 17, 2025 ADC Antibody-Drug Conjugates CDH6 gene cellular targeting NextCure SIM0505 Simcere therapeutic autologous dendritic cells +
Otsuka's Taiho pays $400M for Swiss partner to 'turbocharge' 3 ADCs to clinic on March 17, 2025 Acquisition (action) ADC ADCs Antibody-Drug Conjugates Araris Otsuka 's Taiho +